Welcome to our dedicated page for Bio-Techne news (Ticker: TECH), a resource for investors and traders seeking the latest updates and insights on Bio-Techne stock.
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company whose news flow reflects its role in life science tools, bioactive reagents, diagnostics, and spatial biology. Company announcements frequently highlight financial results, product launches, collaborations, and participation in healthcare and investor conferences, giving investors and researchers insight into how Bio-Techne is executing its strategy.
Recent press releases include quarterly and annual financial updates, where Bio-Techne reports net sales, segment performance for its Protein Sciences and Diagnostics and Spatial Biology segments, and commentary on market conditions. These earnings communications often discuss organic revenue trends, operating margins, and portfolio decisions such as divestitures of non-core businesses.
Product and technology news from Bio-Techne covers launches of analytical instruments, spatial biology assays, and multiomic workflows. Examples include announcements of next-generation protein analysis systems with multiplexing capabilities, spatial biology platforms that combine RNA and protein detection, and assays that visualize protein-protein interactions within tissue at subcellular resolution. Such updates show how the company is expanding its proteomic analytical tools and spatial biology offerings, which it identifies as growth pillars.
Bio-Techne also issues news about strategic collaborations and licensing agreements. Recent items describe partnerships in AI-enabled protein design, multiomic spatial analysis with academic and industry partners, and initiatives supporting cell and gene therapy manufacturing workflows. In addition, the company regularly announces its participation in major healthcare and investor conferences, where management presents its outlook and strategy.
This TECH news page aggregates these types of updates so readers can follow Bio-Techne’s financial reporting, product innovation, strategic partnerships, and conference activity in one place. Investors, analysts, and scientists can use this feed to monitor developments across the company’s life science tools, diagnostics, and spatial biology businesses.
Summary not available.
Summary not available.
Bio-Techne (NASDAQ: TECH) has partnered with Lunaphore to create an automated spatial multiomics workflow aimed at enhancing research in disease analysis and therapeutic development. This collaboration integrates Bio-Techne's RNAscope™ technology with Lunaphore's seqIF™ system for simultaneous detection of protein and RNA biomarkers. The innovative solution promises flexibility in panel designs and is expected to streamline workflows for researchers focused on various diseases, including cancer and neurodegenerative disorders. With RNAscope™'s extensive catalog of over 45,000 probes and proven sensitivity, the partnership aims to significantly accelerate the discovery of novel diagnostics and therapeutics.
Bio-Techne Corporation (NASDAQ: TECH) announced its participation in the American Association for Cancer Research (AACR) annual meeting from April 14-19, 2023, in Orlando, Florida. The company will showcase its extensive portfolio of products aimed at advancing cancer research and facilitating cell and gene therapy development. Featured products include reagents, immunoassays, proteomic instruments, and spatial biology solutions. Several scientists from Bio-Techne will present posters on topics such as biomarkers, structural biology, and spatial biology. Bio-Techne generated approximately $1.1 billion in net sales in fiscal 2022 and employs about 3,000 people globally.
Bio-Techne Corporation (NASDAQ: TECH) will host a conference call and webcast on May 3, 2023, at 8:00 a.m. CDT to discuss its third quarter 2023 financial results. Investors can dial in at 1-877-300-8521 for U.S. calls or 1-412-317-6026 for international calls, using Conference ID 10177426. A rebroadcast will be available for those unable to join live, from 11:00 a.m. CDT on May 3 to 11:00 p.m. CDT on June 3, 2023. Bio-Techne is a leader in developing purified proteins and reagent solutions, generating approximately $1.1 billion in net sales for fiscal 2022 and employing around 3,000 employees globally.
Summary not available.
Bio-Techne Corporation (NASDAQ: TECH) has completed its $257 million investment in Wilson Wolf Manufacturing, acquiring a 20% ownership stake. This investment was initiated after Wilson Wolf met its EBITDA target of $55 million. Bio-Techne has the option to acquire the remaining stake for $1 billion upon Wilson Wolf achieving $226 million in revenue or $136 million in EBITDA by December 31, 2027. If the milestones are not met, Bio-Techne can acquire Wilson Wolf for approximately 4.4 times its trailing revenue. Wilson Wolf is recognized for its innovative cell production technology used in cell and gene therapy.
Bio-Techne Corporation (NASDAQ: TECH) announced its completion of participation in the Cell and Gene Therapy Catapult Process Analytical Technology (Catapult PAT) consortium, a multi-year initiative involving 24 partners. The initiative, which began in January 2021, focused on developing cell and gene therapy-specific analytical technologies. Data was collected during experiments on T-cell expansion bioprocesses, resulting in a first-of-its-kind dataset. The Ella™ platform from Bio-Techne played a key role in the research, which is set to enhance facilities in the UK. Bio-Techne generated approximately $1.1 billion in net sales in fiscal 2022.
Bio-Techne Corporation (NASDAQ: TECH) announced that Jim Hippel, Executive Vice President and CFO, will present at the Barclays Global Healthcare Conference on March 14, 2023, at 2:35 p.m. EDT. A live webcast can be accessed on Bio-Techne's Investor Relations website.
Bio-Techne is a leader in developing high-quality purified proteins and reagents, generating approximately $1.1 billion in net sales in fiscal 2022. The company's extensive portfolio supports biomedical research and diagnostics, enhancing drug discovery and clinical testing.
Bio-Techne Corporation (NASDAQ: TECH) announced an investment of $257 million in Wilson Wolf Manufacturing, resulting in a 20% ownership stake. This follows Wilson Wolf achieving a trailing 12-month EBITDA of $55 million. Bio-Techne can acquire the remaining ownership for $1 billion if Wilson Wolf hits a revenue milestone of $226 million or $136 million in EBITDA by December 31, 2027. Wilson Wolf specializes in innovative cell production technology crucial for Cell and Gene Therapy. The investment is poised to enhance Bio-Techne's capacity in CGT manufacturing and streamline processes in the sector.